Skip to Main Content
HOME
ABOUT US
SOCIAL IMPACT
STRATEGY
GENE THERAPY
CELL THERAPY
RNA-BASED THERAPY
TARGETED THERAPIES
MICROBIOME
TEAM
PORTFOLIO
VENTURE PORTFOLIO
PAST PORTFOLIOS
4BATLE ICAV
NEWS ROOM
CONTACT
More
Use tab to navigate through the menu items.
NEWS ROOM
Mar 24, 2018
TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval
Jan 5, 2018
Takeda announces its intention to acquire TiGenix
ARCHIVE
April 2021
March 2021
January 2021
December 2020
November 2020
October 2020
July 2020
June 2020
May 2020
March 2020
November 2019
September 2019
February 2019
November 2018
August 2018
May 2018
April 2018
March 2018
January 2018
December 2017
SEARCH BY TAGS
portfolio
Orchard Therapeutics
4BIO Ventures II
appointment
approval
investment
ADC Therapeutics
advisory board
Spark Therapeutics
AAV
acquisition
IPO
publication
review
SparingVision
Takeda
TiGenix
4BATLE
awards
BLA
clinical trials
CodeBio
EGLS
Kyowa Kirin
pricing
Redpin Therapeutics
results
venture
FOLLOW US
